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Available online 13 November 2012To obtain a thrombin generation (TG) curve from the conversion of added ﬂuorogenic substrate, thrombin
concentrations are to be derived from the observed velocity of increase of ﬂuorescence (dF/dt). The relation
between velocity and thrombin concentration varies during the experiment because substrate is consumed
and because ﬂuorescence is not linear with the concentration of product.
Here we review the techniques that we developed to:
A: Transform the ﬂuorescence trace into the “ideal” trace that would be seen if substrate consumption and
non-linearity of ﬂuorescence would not play a role.
B: Subtract the contribution of α2M-thrombin so as to obtain the course of free thrombin.
C: Calculate the velocity of prothrombin conversion from the course of free thrombin.
D: Fit a smooth curve through the points obtained in a TG experiment
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To obtain a thrombin generation (TG) curve from the ﬂuorescence
that develops when plasma clots in the presence of a ﬂuorogenic616, 6200 MD, Maastricht, The
16.
emker).
-ND license.thrombin substrate requires a number of calculation steps. They are
routinely carried out by the software that comes with the method.
When such software is unavailable, when it occasionally fails and, in
general, to avoid working with a black box, it is useful to know how
these calculations can be carried out in a spreadsheet.
We developed them over the last few decades and their descrip-
tion and rationale are spread through the methods sections of a num-
ber of articles, mostly dealing with other subjects and therefore not
4 H.C. Hemker, R. Kremers / Thrombosis Research 131 (2013) 3–11easily accessible. In this article we summarize this work systematical-
ly. We do not know in how far these methods are used in the com-
mercial software because it was developed independently by a third
party.
TG was traditionally determined by measuring the thrombin con-
centration in subsamples taken from clotting blood or plasma at reg-
ular intervals, either by measuring the clotting time of a ﬁbrinogen
solution [1–3] or, more convenient, via its amidolytic activity on a
chromogenic substrate [4–7]. In the latter method, thrombin that is
bound to the inhibitor α2Macroglobulin (α2M) is co-estimated, so
that a calculation step is necessary to obtain the curve due to free
thrombin from the experimental data.
Subsampling can be replaced by direct continuous measurement
of the conversion of a thrombin substrate that is added to the plasma
and that releases a colored- or ﬂuorescent group [8–11]. The latter is
preferred because ﬂuorescence, unlike optical density, is not dis-
turbed by the turbidity of a forming clot, so that it is not required to
deﬁbrinated the samples or to inhibit ﬁbrin polymerization. At the
present moment only Z-Gly-Gly-Arg-AMC is in general use as a
ﬂuorogenic substrate but other substrates are likely to emerge.
A substrate is consumed during the experiment so that, as the re-
action proceeds the velocity of product formation (dP/dt) per unit en-
zyme decreases. Moreover ﬂuorescence intensity is not linear with
the concentration of the ﬂuorophore (the so called inner ﬁlter effect)
so that the same reaction velocity (dP/dt) causes increasingly lower
velocities of ﬂuorescence increase (dF/dt) as the experiment proceeds
(Fig. 1).
How to calculate the signal that would be obtained if inner ﬁlter
effect and substrate consumption would not play a role requires cal-
culations that are discussed in the ﬁrst section of this review. In the
second part we show how the course of amidolytic activity can be
split in the parts due to free thrombin and due to α2M-thrombin. In
a third part we discuss how the addition of a thrombin substrate af-
fects the physiological decay process of TG and this inﬂuences can
be quantiﬁed and compensated for. Also we show how the velocity
of prothrombin conversion can be calculated from a TG curve, so
that an inﬂuence of the substrate on the higher steps of the coagula-
tion mechanism can be detected.
Finallywe analyze the effects of experimental noise and showhow it
can be coped with through averaging of curves and curve ﬁtting.
Compensation for Inner Filter Effect and Substrate Consumption
As a starting material for all calculations we use a spreadsheet ﬁle
with the measured ﬂuorescence intensities (F) at a series of known2000
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Fig. 1. Fluorescence increase at ﬁxed thrombin activity and initial substrate concentra-
tion. The conversion of 418 μM ZGGR-AMC by 200 nM α2M-Thrombin was measured
in buffer (red line), 5 normal plasmas (black lines middle bundle) and three plasmas
with visible slight haemolysis (black lines, lower bundle).time points (t) (see tables). From these values the velocity of ﬂuores-
cence increase (the ﬁrst derivative, dF/dt) is calculated (see Annex A).
There is no simple relation between dF/dt and thrombin concentra-
tion. As the experiment progresses, the lower substrate concentration
decreases and the ﬂuorescence – and hence the inner ﬁlter effect -
increases. The over all effect is that, at constant thrombin activity
the measured dF/dt decrease (Fig. 1). The calibration factor (Cf), i.e.
the ﬁgure by which an observed dF/dt has to be multiplied to obtain
the thrombin concentration (Cf=E/(dFt/dt)) therefore steadily in-
creases during a thrombin generation experiment.
In Calibrated Automated Thrombinography (CAT) Cf is deter-
mined at every level of ﬂuorescence from a separate experiment in
which no thrombin generates but where a ﬁxed known amount of
thrombin activity is added.
The calibration factor not only changes in time, it also is different
between buffer and plasma and varies between plasmas (Fig. 1).
Therefore the calibrator experiment is best carried out in the same
plasma as the TG experiment.
Thrombin itself cannot be used for calibration because it is rapidly
inactivated; therefore the stable complex of α2M and thrombin
(α2M –T) is used. In practice 200 nM of this enzyme is employed,
which has an activity equivalent to 100 nM thrombin. The actual
concentration is arbitrary as long as the ﬂuorescence generated in
the calibration experiment covers the same range as those from the
TG well. The total thrombin activity (ETP, see below) that develops
upon normal TG is less than that of 2 μM of thrombin acting for one
minute. A thrombin activity of 100 nM acting for 20 minutes there-
fore will provide an adequate range of calibration signal.
Reading Cf at every level of ﬂuorescence from a separate calibrator
experiment involves awkward numerical procedures. We therefore de-
veloped amathematical transformation, the H-transform, that converts
experimental ﬂuorescence data (Fexp) into ideal data (Fideal), i.e. data
that would have been obtained if inner ﬁlter effect and substrate con-
sumptionwould not play a role [12]. This procedure transforms the cal-
ibrator curve into a straight line, the slope of which gives the Cf. The
same procedure transforms the ﬂuorescence trace from the TG experi-
ment into an “ideal” trace, corrected for substrate consumption and
inner ﬁlter effect.
Application of Cf changes this idealized ﬂuorescence curve into the
integrated thrombin curve, i.e. the value of the ordinate is no longer
arbitrary ﬂuorescence units but t (in min) times E, i.e. the thrombin
concentration in nM. The ﬁrst derivative of the integral thrombin
curve is the TG curve.
From Experimental to Ideal Fluorescence Values
In Fig. 2 we show the ﬂuorescence traces from normal plasma in a
CAT-experiment (black lines). The TG well contains 80 μL citrate
plasma and 20 μL of buffer with tissue factor and phospholipids. At
t=0, 20 μL of ﬂuorogenic substrate and CaCl2 is added. The calibrator
well contains 80 μL of the same citrate plasma and 20 μL of buffer
with α2M-thrombin so as to obtain a ﬁnal concentration of 200 nM,
which is equivalent to 100 nM thrombin. At t=0, 20 μL of ﬂuorogenic
substrate and CaCl2 is added, as in the TG well. Then, using the formu-
la Fideal=α. Arctanh (Fexp/α) the experimental ﬂuorescence values
are converted into the ideal values (red lines). The procedure is
shown in Table 1. In this formula α (alpha) represents a constant,
how it is obtained will be discussed below (See further ref [12] for
the rationale behind this formula and the proof of its applicability).
The slope of the idealized calibrator line (here 25 arbitrary ﬂuores-
cence units per minute is caused by the equivalent of 100 nM throm-
bin, so that the Cf is 4 nM.min/AU, this CF can be used throughout on
the “idealized” curves.
Aside 1: Due to substrate consumption and the inner ﬁlter effect,
experimental ﬂuorescence curves will stop increasing and attain
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Fig. 2. Experimental and idealized ﬂuorescence traces and their derivatives in a TG ex-
periment. Thin black lines: Experimental data TG (upper line) and calibrator (lower
line); bold black line, ﬁrst derivative of experimental TG data. Thin red lines:
Transformed data of the corresponding black curves; bold red line: ﬁrst derivative of
transformed TG data.
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below that the value of α equals the ﬂuorescence intensity at
that plateau. In the approach to this plateau very low values of
dF/dt are measured from the difference of very high ﬂuorescence
intensities, which causes high experimental noise. In practice ﬂuo-
rescence intensities higher than 0.8 times α are therefore better
discarded.
Aside 2: H-transformation is an approximation. Correction onbasis of
the theory behind substrate consumption and inner ﬁlter effect is to
be preferred over the approximation via the H-transform. This, how-
ever, would require to know the kinetic parameters of substrate con-
sumption (Km and kcat ) as well as the parameters that characterize
the innerﬁlter effect (ﬂuorescence yield, optical densities, parameters
related to measuring cell geometry). The variable quenching of ﬂuo-
rescence in plasma and the variable binding of substrate to plasma
proteins make that these constants vary between individual plasmas
and cannot be imported from independent experiments. Correcting
the curves in a given sample would thus require ﬁnding ﬁve pa-
rameters from one curve. This is theoretically difﬁcult and practi-
cally impossible. H-transformation needs only one parameter: α.
The Diagnostic Plot
H-transformation in practice means applying a simple formula to
the experimental ﬂuorescence data. When substrate consumptionTable 1
Correction for substrate consumption and inner ﬁlter effect.
A B C D E
1 Time
(min)
Fl. Exp.
(AU)
Fl. Ideal.
(AU)
dFl.Ideal/dt
(dAU/dt)
2 0 0 0 0 α
3 0.5 F1 =E$2.arctanh (B3/E$2) =(C3-C2)/N
4 1 F2 =E$2.arctanh (B4/E$2) =(C4-C3)/N
5 1.5 F3 =E$2.arctanh (B5/E$2) =(C5-C4)/N
etc. …. …. …. ….
22 10 F20 =E$2.arctanh (B22/E$2) =(C22-C21)/N
etc. …. …. …. ….
32 15 F30 =E$2.arctanh (B32/E$2) =(C32-C31)/N
Fl.Exp. = Experimentally found ﬂuorescence intensity.
Fl.Ideal. = Fluorescence intensity corrected for substrate consumption and inner ﬁlter
effect. AU=Arbitrary Units. N= number of sampling points per min (=2).α=Constant
that is to be changed until ﬂuorescence increases linearly when amidolytic activity is con-
stant (see text).and inner ﬁlter effect are to be corrected for, another formula has to
be used than when only one of these two disturbing effects occurs.
Substrate consumption may become negligible when the kinetic con-
stants of a substrate are particularly favorable. Inner ﬁlter effect is ab-
sent when measurements are carried out in thin layers.
To decide what formula should be applied we make a “diagnostic
plot”, i.e. a plot of the experimental ﬂuorescent signal obtained at
constant thrombin activity, e.g. with the calibrator (α2M-T) against
its own ﬁrst derivative (Fig. 3). When this plot is a horizontal straight
line (y=constant), the reaction velocity does not vary as the reaction
proceeds and no correction is necessary (the black curve in Fig. 3).
When the diagnostic plot is a straight line with a (necessarily
downward) slope (the blue curve in Fig. 3) the formula that trans-
forms the experimental data (Fexp) into ideal data (Fideal) is
Fideal ¼−α: Ln 1−Fexp=α
 
ðAÞ
When, which is usually the case, the diagnostic plot is a downward
sloping parabola (the red curve in Fig. 3) then the formula to be used
is:
Fideal ¼ α: Arctanh Fexp=α
 
ðBÞ
In these formulae α is a constant equal to the value of ﬂuorescence
at the point where the diagnostic plot intersects with the abscissa. At
that point dF/dt=0, i.e. ﬂuorescence no longer increases as the reac-
tion proceeds. Therefore α equals the experimental plateau value of
ﬂuorescence.
Aside 1: The intercept of the diagnostic plot with the ordinate is
the initial reaction velocity. It should be higher than any of the veloc-
ities measured because neither substrate consumption nor inner ﬁlter
effect will as yet play a role. When the highest velocities are found
after zero time (e.g. the middle curve of Fig. 3, right frame) the sam-
ple is warming up inside the ﬂuorometer. The diagnostic plot thus in-
dicates incorrect thermostation.
Aside 2: When the diagnostic plot is a straight line, this means that
the decrease of the reaction velocity at constant enzyme activity is
linearly proportional with the level of ﬂuorescence and due to either
substrate consumption or inner ﬁlter effect. When it is a parabola this
shows that the decrease is due to the two linear processes that super-
impose and the effects of which multiply. There is no a priori mecha-
nistic reason why it should, however, and it needs not to do so over
the complete course of the experimental values. Therefore the appli-
cability of the H-transform is limited to the range in which the diag-
nostic plot is a straight line (one disturbing process) or a parabola
(two).
Determining Alpha
The correct value for α is that value that converts the ﬂuorescent
signal into a straight line when the amidolytic activity is constant.
Constant, thrombin-like amidolytic activity in plasma is always due
to the α2M-thrombin complex because free thrombin is subject to
rapid decay. Α2M-thrombin appears under two circumstances:
When it is added as a calibrator and when it remains in the serum
after TG is over. Both instances can be used to determine the value
of α.
A: from a Reference Curve
Determining α from a calibrator curve is shown in Fig. 4. The left
frame contains the experimentally found curve (blue) and the other
lines are transformed data prepared with the formula Ftransformed=
α. Arctanh(Fexp/α) at different values of alpha. The right value of
alpha is that one that converts the experimental data into a straight
line and hence the ﬁrst derivative into a horizontal line. The easiest
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Fig. 3. Diagnostic plots. L: Experimental data obtained at constant enzyme activity; black: neither inner ﬁlter effect nor substrate consumption; blue: either inner ﬁlter effect or
substrate consumption; red: both inner ﬁlter effect and substrate consumption R: Diagnostic plots, i.e. dF/dt from the curves in the left frame plotted against F.
6 H.C. Hemker, R. Kremers / Thrombosis Research 131 (2013) 3–11way to ﬁnd alpha is taking the ﬁrst derivative, pass a trend-line
through the values and alter α until that trend-line is horizontal
(Fig. 4 right frame).
A good ﬁrst estimate of α is the maximal value of the experimen-
tal ﬂuorescence (blue line in the left frame of Fig. 4).
The intercept of the horizontal trend-line with the ordinate is the
slope of the reference curve, i.e. the slope of a transformed curve caused
by 100 nM of thrombin activity (=200 nM of α2M-thrombin). If
this value is 30.15 AU/min, as in Fig. 4, that the calibration factor
(Cf) that converts dAU/dt values in thrombin concentrations=
100/30.15 (nM/(dAU/dt)).
B: from a TG Curve
It is possible to determine alpha from the end-part of a TG curve,
i.e. from the continuous α2M-thrombin activity that remains when
TG is over. Fig. 5 is the equivalent of Fig. 4 but now carried out on the
ﬂuorescence data from a TG experiment. The procedure is essentially
the same as for a calibration curve. Only, here the trend line should be
drawn only through that part of the curve that is obtained at constant
amidolytic activity, i.e. when TG is over and only α2M-thrombin
remains.
Again the intercept of the horizontal trend line with the ordinate
gives the dAU/dt value (10.11 in Fig. 5) that corresponds to the con-
stant activity that remains in the plasma (“serum”) mixture after
the experiment is over. This activity can be determined independent-
ly, by measuring the amidolytic activity in the remaining ﬂuid with a
traditional chromogenic substrate. When it shows an acivity equiva-
lent to 33 nM thrombin activity, the value of 10.11 for d (AU)/dt is3000
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Fig. 4. Determining α from a calibrator curve. L: Blue: experimental data; black lines: transfo
R: First derivatives of the lines in the left frame. The formula describes the best straight line
the intercept (30.15).known to correspond to 33 nM of thrombin. The calibration factor
then is Cf=33/10.11. In this manner one can obtain a calibrated
TG-curve without having to run a calibrator in parallel [12].
It is often seen that the value of α that is found in a TG experiment
is not exactly the same as that found in the corresponding calibration
experiment. This is because the maximum ﬂuorescence that can be
attained in different mixtures can be different, e.g. by slight differ-
ences in optical density or light scatter (e.g. due to ﬁbrin formation).Subtraction of the α2M-thrombin Activity
With small substrates one measures the combined amidolytic ac-
tivity of free thrombin and the a2M-thrombin complex. The formation
of α2M-thrombin can be suppressed by chemical means but not
completely [13]. It is possible, however, to mathematically dissect
the amidolytic activity into the part due to free thrombin and that
due to α2M-thrombin [14].
A2M-thrombin is formed during TG from free thrombin and plas-
matic α2M in a reaction that is pseudo ﬁrst order, because the con-
centration of α2M is much higher (3–6 μM) [15] than that of free
thrombin (b500 nM) at any moment and the over all consumption
of α2M during coagulation is limited (b .5 μM) [16]. The velocity
with which α2M-thrombin is formed therefore is proportional to
the concentration of thrombin. The rate constant of this reaction (k)
is such as to obtain the stable end amidolytic activity. (When a revers-
ible direct thrombin inhibitor is present these assumptions do not
apply, see further [17]).y = -0.0004x + 30.15
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Fig. 5. Determining α from a TG curve. L: Blue: experimental data; black lines: transformed lines at arbitrary values of α; red line: transformed line at the correct value of α. R: First
derivatives of the lines in the left frame.
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thrombin is calculated as the difference of the amidolytic activity
measured (column B) and the amount of α2M-thrombin activity
build up (column D). The latter is calculated, again at each point in
time, as the sum of the previous amount plus the fraction (k=$E
$1) of free thrombin that turns into the α2M-thrombin complex.
The right value of k is that one that brings the concentration of free
thrombin in the end to zero, without passing through signiﬁcant neg-
ative values (Fig. 6).
A completely identical procedure can be carried out on the
idealised ﬂuorescent trace before making the ﬁrst derivatives. The cri-
terion then is that a corrected ﬂuorescence curve is obtained that
rises to a constant (“horizontal”) end level that is higher than any
other point of the trace (Fig. 7).Inﬂuence of the Substrate on Physiological Thrombin Inactivation
Inﬂuence of Substrate on Thrombin Decay and TG Parameters
From some moment after the peak the decay phase of TG is in good
approximation a mono-exponential process, as can be seen when a
thrombin concentrations are plotted on a logarithmic scale. It thus is
characterized by a (pseudo monomolecular) decay constant (kdec).
The presence of a thrombin substrate inﬂuences the TG process be-
cause it occupies the active centre of thrombin. Thenatural antithrombins
attack on the active centre, so their inhibitory capacity is proportional toTable 2
Subtraction of the α2-macroglobulin activity.
A B C D E
1 Time
(min)
Amid.Act
(nM)
Thrombin
(nM)
α2M-Thrombin
(nM)
2 0 0 0 0 K
3 0.5 Tg1 =B3-D3 =D2+$E$2*C2 P
4 1 Tg2 =B4-D4 =D3+$E$2*C3
5 1.5 Tg3 =B5-D5 =D4+$E$2*C4
etc. …. …. …. ….
22 10 Tg20 =B22-D22 =D21+$E$2*C21
etc. …. …. …. ….
32 15 Tg30 =B32-D32 =D31+$E$2*C31
A: sampling time,
B: Amidolytic activity expressed in nM thrombin, obtained from column D in Table 1 by
multiplication with the calibration factor.
C: Activity of free thrombin.
D: activity of α2Macroglobulin-thrombin.
E2: K=Decay constant due to α2Macroglobulin divided by the number of sampling
points per minute (=2).
E3: P=sum of an arbitrary number of thrombin values (column C) in the last part of
the curve (see text). P should be set to zero by changing K.the fraction of active centers that is not occupied by substrate. At a sub-
strate concentration S, a fraction of Km/(Km+S) of the enzyme is free,
so the decay velocity is diminished by Km/(Km+S) (kdec.observed=
kdec.natural.(Km+S)/Km)). If the rate of prothrombin conversion re-
mains the same, this will cause all thrombin concentrations to be
augmented by a factor (Km+S)/Km and consequently the peak
and the ETP as well.
If ETPS is the ETP found with a substrate used at a concentration S
and ETPN the “natural” ETP that would be found in the absence of sub-
strate, then ETPS=(Km+S)/Km) ETPN. In the standard CAT assay [9],
peak and ETP are about 1.5 times bigger than they would be if no sub-
strate were present.
Inﬂuence of the Substrate on Prothrombin Conversion
A substrate occupies active centers and therefore inhibits throm-
bin but prolongs its lifetime. It is difﬁcult to predict what the over
all effect will be on the many thrombin driven feedback reactions in
the coagulation system (activation of factors V, VIII, XI and protein
C) [18]. Also a thrombin substrate needs not be completely speciﬁc
for thrombin and may bind to, and thus inhibit, other serine proteases
of the clotting system (the activated factors VII, IX, X, XI, XII and kal-
likrein). Such binding may or may not lead to product formation. The
concentrations of the activated clotting factors are so much lower
than that of thrombin that disturbing product formation will be min-
imal. (With the exception of kallikrein that may cause a low constant
background activity in contact activated plasma with certain chromo-
genic thrombin substrates (unpublished observation)).
In any case an inﬂuence of a thrombin substrate on the prothrom-
bin conversion process is not a priori unlikely and should be excluded
experimentally [11,19]. To calculate the course of prothrombin con-
version is a useful technique also to investigate the effect of heparin
(−like) s and direct inhibitors of factors Xa, IXa and VIIa.
The rate of prothrombin conversion is the observed rate of change
of thrombin to which the rate of thrombin disappearance is added.
The latter can be calculated by multiplying the thrombin concentra-
tion with the decay constant (kdec). This is allowed because, as we
see in Fig. 8, the decay of thrombin is in good approximation
semi-logarithmic, hence proportional to the thrombin concentration.
The observed rate of change of the concentration of thrombin is
the ﬁrst derivative of the TG curve. The rate of disappearance is kdec
times the thrombin concentration at any moment (i.e. the TG curve)
(Fig. 9). The rate of prothrombin conversion therefore is equal to
the ﬁrst derivative of the TG curve plus the decay constant (kdec)
times the TG curve (Fig. 9). The calculation is again carried out in a
spreadsheet (Table 3).
The decay constant (kdec) can be read from curves as in Fig. 8;
where it is 0.30 min-1 in normal plasma and 0.55 min-1 in deﬁbrinat-
ed plasma (corresponding to half life times of 2.3 and 1.3 min); kdec
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Fig. 6. Subtraction of α2macroglobulin activity from a TG curve. Blue: Idealised amidolytic activity curves. Black: Idealised amidolytic activity curve after α2M-thrombin correction
procedure at arbitrary values of k. Red line: α2M-thrombin correction procedure at the correct value of k. L: deﬁbrinated plasma. R: normal plasma.
8 H.C. Hemker, R. Kremers / Thrombosis Research 131 (2013) 3–11can also be found in the spreadsheet calculation as the lowest value
that will not lead to signiﬁcantly negative values of the prothrombin
conversion curve (Fig. 10).
As an illustration, in Fig. 11 the prothrombin conversion curve is
shown for normal plasma and in normal deﬁbrinated plasma. It ap-
pears that the appreciable positive effect of the presence of ﬁbrin on
TG is not so much due to an effect on prothrombin conversion but pri-
marily to an attenuating effect on thrombin decay. The demonstration
of the very limited importance of anti-factor Xa activity in most types
of heparins is another example of the utility of this approach [7,20].
Aside 1: The TG curve is obtained as a ﬁrst derivative of the
transformed ﬂuorescence curve, so the net velocity of the TG curve
is a second derivative of the (idealised) ﬂuorescence curve. It there-
fore is beset with experimental noise. That is why it is useful to ﬁrst
ﬁt a smooth curve through the TG curve; alternatively experimental
noise can be suppressed by taking the average of several experi-
ments (see further below).
Aside 2: Theoretically the calculation of prothrombin conversion ve-
locities is an approximation. It is only valid in so far as the decay of
thrombin can be assumed to be semi-logarithmic; i.e. as long as
the consumption of antithrombin during the experiment does not
have to be taken into account [16]. From Fig. 8 it can be seen that
this is the case during an appreciable part of the decay phase.
Noise
From a series of 16 calibrator curves we calculated the average at
each time point (F) as well as the standard deviation (SD) and the co-
efﬁcient of variation (CV, i.e. SD as a % of F). The CV was constant at11200
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Fig. 7. Subtraction of α2macroglobulin activity from a ﬂuorescence curve. L: Deﬁbrinated pl
black: same data after the α2M-thrombin correction procedure at arbitrary values of k; red1.9 % so the experimental error is a ﬁxed small percentage of the ﬂuo-
rescence value (Fig. 12, left frame). When the same is done for a TG
experiment, a very different picture is seen (Fig. 12 right frame). For
the values of ﬂuorescence found around the peak of TG the error is
much larger than ~2 %. Only when thrombin is no longer generated
the error decreases to levels comparable with that of the calibrator
(2.7%).
The reason is that in a TG curve samples are measured at ﬁxed
time intervals. Even if the ﬂuorescence curves would have exactly
the same form, the experimental variation in the lag time would be
counted as an experimental variation in ﬂuorescence intensity (see
Fig. 13). The experimental variation in the lag time depends upon
the reaction conditions. At ≥5pM tissue factor it is small, in platelet
rich plasma without added tissue factor it may amount to minutes.
When it is that large, averaging of curves becomes senseless. In
these cases one should determine the time to peak ﬁrst and shift
the curves along the time axis so as to align the peaks. This is a te-
dious procedure to do in a spreadsheet. The easiest way to get rid of
experimental noise is to determine the ETP, peak and time to peak
of each individual curve and, using the average values found, then
ﬁt a curve through the experimental data (see below).The Lag Time
It is commonpractice to determine the lag-time as themomentwhen
the TG curve rises systematically above an arbitrary level; e.g. 10 nM or a
ﬁxed fraction of the peak. This has the drawback that,when the threshold
is chosen low, accidental noise can simulate an unrealistically short lag
time and when it is chosen high, signiﬁcant TG occurs during the lag
time so that the lag-time is overestimated and a part of the rising curve200
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Table 3
Calculation of Prothrombin conversion velocity.
A B C D E F
1 Time Thr. dThr./dt Decay Pr. conv.
2 0 0 0 0 0 kdec
3 0.5 T1 =(B3-B2)/N =F$2*B3 =C3+D3
4 1 T2 =(B4-B3)/N =F$2*B4 =C4+D4
5 1.5 T3 =(B5-B4)/N =F$2*B5 =C5+D5
Etc. …. …. …. …. ….
22 10 T20 =(B22-B21)/N =F$2*B22 =C22+D22
Etc. …. …. …. …. ….
32 15 T30 =(B32-B31)/N =F$2*B32 =C32+D32
Etc. …. …. …. …. ….
Thr.: Thrombin concentration; dThr/dt: Rate of change of thrombin concentration;
Decay: Thrombin decay velocity; Prothr. conv.: Velocity of prothrombin conversion.
N=number of sampling points per min (=2).
G2=Decay constant of thrombin, the value that should be increased until E is minimal
without becoming signiﬁcantly negative.
9H.C. Hemker, R. Kremers / Thrombosis Research 131 (2013) 3–11is included into the lag-time, inducing a spurious correlation between
lag-time and ETP.
In practice the lag time is best estimated directly from the ﬂuores-
cence intensity rather than from the TG curve because ﬂuorescence
reﬂects the cumulative effect of thrombin and thus the increase of
signal will reach signiﬁcance earlier.
A strategy to determine signiﬁcant rise is to determine the average
plus one standard deviation of all points from zero time on (f0). If the
points n+1, n+2 and n+3 are all three signiﬁcantly (+1 SD)
higher than the average of the points from zero up to n, one can con-
sider the curve to have left baseline.
This has the additional advantage of determining the base level,
i.e. the background ﬂuorescence, which then can be subtracted from
all other ﬂuorescence values so as to start at zero. This is required
when a small amount of ﬂuorescent material is added to the sample
to serve as an internal reference [21] or when substrates are used
with a ﬂuorescence at the same wavelength as the product.
Curve Fitting
Fitting a smooth curve through the experimental points of a ﬁn-
ished TG experiment allows mitigating the effects of experimentalFig. 9. Calculation of prothrombinase activity. Black: Change in thrombin concentration
per min; Blue: Thrombin decay; Red: Thrombin production.noise. It is easiest done on the integrated thrombin curve (Fig. 14,
see also sub 1.1). In this curve the Y axis represents the area under
the TG curve up to that moment. The end level of this curve, evident-
ly, is the ETP.
Once the time to peak (τ), the peak (π) and the ETP (ε) have been
determined it is often possible to draw a smooth line through the ex-
perimental points of the integral curve using the following formu-
la [22]
T ¼ ε:n:exp −expð− t−τð Þ:kdecð Þ ðCÞ
Here kdec is the decay constant of thrombin that can be deter-
mined from a graph as in Figs. 8 or 10 or calculated from Π and Ε by
the following relation
kdec ¼ 2:72:π=ε ðDÞ
leading to the alternative formula
T ¼ ε: n:exp −expð− t−τð Þ 2:72:π=εð Þð Þ ðEÞ
The constant 2.72 is the basis of the natural logarithm (e), N is the
number of measuring points per minute.
If this curve does not ﬁt to the experimental data within the limits
of experimental error, a formula of the same form can be added [22]
but then the simple relations between the constants of the formula
and the parameters of the TG process (Τ, π, Ε) are lost. When the
ETP curve has been ﬁtted the TG curve is easily found as its derivative.100
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From the subcommittee on factors VIII and IX of the ISTH, a report
on the standardization of methods for performing the thrombin gen-
eration test is in preparation at this moment [23]. From this report it
emerges that calibrated automated thrombinography [9] can now be
executed with an inter laboratory variation of 6 – 11 %, i.e. not worse
than the determination of e.g. factor VIII or IX. The major pitfalls are
not in the calculation method but in the preanalytical treatment of
the sample, notably in aspiring cell material when preparing plasma
[24], and in insufﬁcient temperature control [25].
It is good to realize that TG increases as the temperature drops. It
also increases upon moderate dilution of the sample [26,27]. These
counterintuitive phenomena are due to the fact that dilution and low-
ering of the temperature have much more inﬂuence on thrombin
decay than on prothrombin conversion.
The major problem with thrombin generation methods in general
remains with calibration. Calibration with a standard thrombin [28,29]
cannot be carried out in plasma because of the antithrombins. If buffer
is used instead, errors are introduced due to the fact that thrombin ac-
tivity and ﬂuorescence yield are not the same in buffer and in plasma
and also differ between individual plasmas (Fig. 1). For this reason
α2M-thrombin, added to the same plasma as that in which TG is mea-
sured is used in the CAT technique.
If one wants to obtain information on the entire process of TG, it is
crucial that the substrate should not exhaust before TG is over. There500
0
SD
 (A
U)
0 15000
Fluorescence Signal (AU)
Fig. 12. Standard deviation of the ﬂuorescence signal as a function of the mean. Left fraexists a relatively large number of methods in which such substrate
exhaustion does occur. This is a fortiori the case when the natural sub-
strate ﬁbrinogen is monitored, either by optical or by mechanical
means, i.e. in thrombelastography and in turbidity analysis [30–32].
It also occurs when a fast thrombin substrate is used [17] and with
electrochemical substrates [17,31]. Such methods generate curves
that are difﬁcult to distinguish from real TG curves but the decay
phase is due to substrate consumption and not to thrombin inactiva-
tion. Consequently the curves do not contain information on the latter
part of the course of thrombin generation and notably do not allow to
assess the total amount of thrombin activity that is formed, i.e. the
ETP.Conﬂict of Interest Statement
The authors are emplyees of Synapse BV, a research company
owned by Diagnostica Stago. C.H. is consultant to Diagnostica Stago.Annex A. Calculation of Derivatives in a Spreadsheet
When the ﬂuorescence intensities in the course of time, as
obtained from the ﬂuorometer, are entered in a spreadsheet, as in
Table 4, differentiation of the ﬂuorescence values reduces to simple
subtraction. If we look at row 8 and 9 in column B and C of Table 4,
it is evident that the velocity of change of the ﬂuorescence signal
equals (47.8 – 33.9) AU per quarter of a minute. In general terms:
dF/dt n=(cfn-cfn-1)/(tn-tn-1).500
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me: Calibration experiment; Right frame: TG experiment. Normal plasma; N=16.
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Fig. 14. The Integral thrombin curve. Black: TG curve; Red: Integrated TG curve.
Table 4
Calculation of ﬁrst derivatives.
A B C D F G
1 Time Cal TG dCal/dt dTG/dt
2 min. AU AU dAU/dt dAU/dt
3 0 0 0
4 0.25 8.3 0.6 33.3 2.3
5 0.5 16.3 0.7 32 0.4
6 0.75 24.1 0.7 31.2 0.2
7 1 28.7 0.8 31.2 0.3
8 1.25 33.9 1.2 31.8 1.5
9 1.5 47.8 2.2 31.5 4.3
10 1.75 55.7 3.8 31.6 6.4
11 2 62.4 4.9 26.9 4.2
12 2.25 70.2 9.3 31 17.6
13 2.5 78 17 31.2 30.9
(Cal: ﬂuorescence values from calibrator well; TG: Fluorescence values of thrombin
generation well; AU: arbitrary units.)
11H.C. Hemker, R. Kremers / Thrombosis Research 131 (2013) 3–11It is a nasty property of the ﬁrst derivative to be much noisier than
the original signal is. Upon subtraction of two values the errors add,
which results in a large error to a small value. Noise can be reduced
by calculating the derivative of a moving average. This is done by
subtracting experimental points that are a number of cells apart.
The derivative of a moving average over three points is obtained as
(tgn+1-tgn-1)/(tn+1-tn-1), that over ﬁve points as (tgn+2-tgn-2)/
(tn+2-tn-2). The drawback of a moving average is that it blunts the
peak. Whether this is signiﬁcant or not depends on the frequency of
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